Straumann® Emdogain®

Mastering periodontal regeneration and oral wound healing.





Straumann® Emdogain® is a unique gel containing enamel matrix derivative. This mixture of natural proteins can induce biological processes that usually take place during the development of the periodontium and may stimulate certain cells involved in the healing process of soft and hard tissues.


30 years Emdogain®

Emdogain - 30 years in the market

1.700 scientific publications (>600 clinical)19

>3 million patients treated globally20

Extremely well tolerated21

Long-term stable results documented22

Clinical follow-up of >29 years with successful results

Unique  and pioneer23

Approved in +90 countries24

Clinical Case Book

For 30 years, Emdogain has set new standards in periodontal regeneration—delivering lasting results backed by science and trusted by experts worldwide.

To celebrate this remarkable milestone, we’ve created an exclusive Clinical Case Book that brings Emdogain’s legacy to life. This collection captures the essence of our journey with detailed clinical cases, innovative techniques, and long-term results, enriched by insights from the world’s leading clinicians.

  • 32 clinical cases
  • Up to 29 years follow-up
  • +20 nationalities
  • 7 indications
  • KOL and patients testimonials
  • Interviews

Register to download the case book

Are you using Emdogain already?*
Data usage agreement*

Read our privacy notice.

Please retype the code above

32 clinical cases

Up to 29 years follow-up

+20 nationalities

7 indications

KOL and patients testimonials

Interviews

Features and benefits

Emdogain® induces true regeneration

By modulating the wound healing process, Emdogain® induces the regeneration of a functional attachment in periodontal procedures (as evidenced by human histological data⁵,⁶)

Emdogain® improves wound healing in oral surgical procedures

By promoting angiogenesis modulating the production of factors related to inflammation⁹ and thanks to its anti-microbial effect toward oral pathogens Emdogain® accelerates the wound healing process of oral surgical procedures

Emdogain® increased the predictability of your periodontal procedures

Emdogain® leads to:
– significantly improved clinical parameters in intra-osseous defects compared to open flap debridement procedures alone12
– increased root coverage achieved when used in a coronally advanced flap (CAF) compared to CAF alone13, and leads to results comparable to CAF + Connective Tissue Graft14 

Emdogain® helps you achieve patient satisfaction

– When used to treat intra-osseous defects, Emdogain® contributes to improve your patients’ dental prognosis
– When used in oral surgical procedures in general, Emdogain® accelerates wound closure15, and reduces post surgical pain and swelling16
– When used in periodontal plastic procedures around teeth and implants, Emdogain® may improve the esthetics of the results thanks to improved wound healing

Emdogain® is easy to apply

Because Emdogain® is a gel, it is easy to apply, even in defects difficult to access

 

Emdogain® means peace of mind

Emdogain® is backed by extensive and long term clinical documentation. It is documented in over 1000 scientific publications including 600 clinical publications17 and 10 year data14,18

Brochures and videos

Looking for additional information? You'll find them in the Download Center.


Straumann® Emdogain® on youTooth


All Straumann® Emdogain® Solutions

Contact us

Data usage agreement*

Read our privacy notice.

Please retype the code above

References

5 McGuire MK, et al. A Prospective, Cased-Controlled Study Evaluating the use of Enamel Matrix Derivative on Human Buccal Recession Defects: A Human Histologic Examination. J Periodontol. 2016 Feb 1:1-34.
6 Sculean A, et al. Clinical and histologic evaluation of
human intrabony defects treated with an enamel matrix protein derivative (Emdogain). Int J Periodontics Restorative Dent. 2000;20:374–381.
7 Aspriello SD, et al. Effects of enamel matrix derivative on vascular endothelial growth factor expression and microvessel density in
gingival tissues of periodontal pocket: a comparative study. J Periodontol. 2011 Apr;82(4):606-12.
8 Guimarães et al. Microvessel Density
Evaluation of the Effect of Enamel Matrix Derivative on Soft Tissue After Implant Placement: A Preliminary Study. Int J Periodontics Restorative
Dent. 2015 Sep-Oct;35(5):733-8.
9 Sato et al. Enamel matrix derivative exhibits anti-inflammatory properties in monocytes J Periodontol.
Mar 2008;79(3):535-40
10 Arweiler et al. Antibacterial effect of an enamel matrix protein derivative on in vivo dental biofilm vitality. Clin Oral Investig. 2002 Dec;6(4):205‑9. Epub 2002 Nov 14.
11 Maymon-Gil T, et al. Emdogain Promotes Healing of a Surgical Wound in the Rat Oral Mucosa. J. Periodontol. 2016 Jan 16:1-16.
12 Tonetti et al. Enamel matrix proteins in the regenerative therapy of deep intrabony defects – A multicenter,
randomized, controlled clinical trial. J Clin Periodontology 2002;29;317-325
13 Tonetti MS et al. Clinical efficacy of periodontal plastic surgery
procedures: consensus report of Group 2 of the 10th European Workshop on Periodontology. J Clin Periodontol. 2014 Apr;41 Suppl 15:S36-43
14 McGuire MK, et al. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or
connective tissue: comparison of clinical parameters at 10 years. J Periodontol. 2012 Nov;83(11):1353-62
15 Villa O et al. J Periodontol. A Proline-Rich Peptide Mimic Effects of EMD in Rat Oral Mucosal Incisional Wound Healing. 2015 Dec;86(12):1386-95.
16 Jepsen S, et al. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal Class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes.J Periodontol. 2004 Aug;75(8):1150-60.
17 According to PUBMED - search term “Emdogain" or "enamel matrix derivative”.
18 Sculean A, et al. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue
regeneration. J Clin Periodontol. 2008 Sep;35(9):817-24
19 According to PUBMED search for “Emdogain” or “enamel matrix derivative”.
20 Based on the number of syringes sold to date globally.
21 Based on a global post-surgical complication rate of less than 0.003%.
22 based On 2 indications: intrabony defects and recession coverage. (+10years clinical evidence)
23 Based on PI / unique patented formulation
24 Regulatory approvals per country